Tilray Brands, Inc. Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)
Tilray Brands, Inc. (TLRY) reported Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) of -$546.00 thousand for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-28.
Financial Statements › Notes
us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease · last filed 2026-07-28
- Tilray Brands, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2026 was -$546.00K.
- Tilray Brands, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2025 was -$4.01M, a 473.90% decline from fiscal 2024.
- Tilray Brands, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2024 was $1.07M, a 13.26% decline from fiscal 2023.
- Tilray Brands, Inc. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2023 was $1.24M, a 48.50% increase from fiscal 2022.
| Period end | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 12 month |
|---|---|
| 2026-05-31 | -$546.00K 10-K · filed 2026-07-28 |
| 2025-05-31 | -$4.01M 10-K · filed 2026-07-28 |
| 2024-05-31 | $1.07M 10-K · filed 2026-07-28 |
| 2023-05-31 | $1.24M 10-K · filed 2025-07-29 |
| 2022-05-31 | $833.00K 10-K · filed 2024-07-30 |
| 2021-05-31 | $2.26M 10-K · filed 2023-07-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |